The Future Of Vaccine Development And Manufacturing: The Benefits Of Combining IDT Biologika's MVA Technology Platform With Innovative Analytical Methods

Modified Vaccinia Ankara (MVA) is a highly attenuated strain of the vaccinia virus, which is a member of the poxvirus family. MVA has been used as the basis for several vaccines, particularly as a vector for the other vaccine antigens e.g. Malaria, HIV, HBV, and SARS-CoV-2 and is also used in several studies as a booster or second shot after an e.g. AdV vector vaccination. Beside the clinical data, there are already products on the market like the smallpox vaccine from BD and the Ebola vaccine from Janssen.

Several advantages of the MVA are that it can stimulate both the humoral and the cell mediated immune response and that it was indicated in several prime-boost regimes as being highly immunogenic. It is also well tolerated by immunocompromised people. IDT Biologika itself started to work with MVA in 1997 and we have built up a broad knowledge in the manufacturing of these viral vectors - alone and with partners worldwide. We continually strive to further develop this platform and challenge our own capabilities and technologies.

View the webinar to learn how innovation in process development technologies is impacting vaccine manufacturing and how IDT Biologika is supporting the product life cycle from process and analytical development through every stage of clinical trials and eventual commercialization.